Griffith University researchers have played a key role in using DNA ‘origami’ templates to control the way viruses are assembled.
With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies
Seattle startup Outpace Bio, a Lyell Immunopharma spinout using AI to design proteins for solid tumor cell therapies, has raised a $144 million Series B